Immunocore Holdings (IMCR) revenue breakdown
By product, Revenue from sale of therapies, net is the largest at 100% of fiscal 2024 revenue, growing 48% a year over 2 years.
By region, United States is the largest at 64% of fiscal 2025 revenue; Europe grew fastest, 252% a year over 3 years.
Revenue by product
Fiscal years, as Immunocore Holdings reports them in its 10-K filings; fiscal 2024 total $310M.
| Products | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|---|
| Revenue from sale of therapies, net | — | — | — | $141M | $239M | $310M | 100% |
| Collaboration revenue | — | — | — | $34M | $11M | $213,000 | 0% |
| Genentech | $1M | $19M | $20M | — | — | — | — |
| Med Immune | $8M | — | — | — | — | — | — |
| GlaxoSmithKline | $6M | $6M | $6M | — | — | — | — |
| Eli Lilly | $9M | $819,000 | $4M | — | — | — | — |
Revenue by region
Fiscal years, as Immunocore Holdings reports them in its 10-K filings; fiscal 2025 total $400M.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| United States | $18M | $20M | $24M | $17M | $97M | $170M | $257M | 64% |
| Europe | — | — | — | $3M | $43M | $68M | $131M | 33% |
| International | — | — | — | — | $1M | $1M | $12M | 3% |
| United Kingdom | $6M | $6M | $6M | $6M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IMCR.
Open IMCR in InvestinglyQuestions
Where does Immunocore Holdings make its money?
In fiscal 2024, by product: Revenue from sale of therapies, net $310M, Collaboration revenue $213,000.
From Immunocore Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.